Renal disease News and Research

RSS

Finerenone drug improves albuminuria among patients with diabetes and kidney disease

Among patients with diabetes and kidney disease, most receiving an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, the addition of the medication finerenone compared with placebo resulted in improvement in albuminuria (the presence of excessive protein [chiefly albumin] in the urine), according to a study in the September 1 issue of JAMA.

2 Sep 2015

DaVita Kidney Care to establish kidney care specialty hospital chain in Shandong province China

DaVita Kidney Care, a division of DaVita HealthCare Partners Inc. (NYSE: DVA) and a leading global provider of kidney care services, today announced it is forming a joint venture kidney care specialty hospital chain in Shandong province China.

31 Aug 2015

Symic receives $1.5M NIH Phase II SBIR grant to develop AVF therapeutic candidate

Platform therapeutic company Symic Biomedical, Inc. announced today that it has received a $1.5M Phase II SBIR grant from the National Institutes of Health to further develop its therapeutic agent to reduce arteriovenous fistula (AVF) failures, a significant unmet clinical need in end stage renal disease (ESRD) patients undergoing hemodialysis.

27 Aug 2015

Only 1 in 4 patients with ESRD in Georgia referred for kidney transplant evaluation

Only about one in four patients with end-stage renal disease in Georgia were referred for kidney transplant evaluation within 1 year of starting dialysis between 2005 and 2011, although there was substantial variability in referral among dialysis facilities, according to a study in the August 11 issue of JAMA.

12 Aug 2015

Isis Pharmaceuticals, AstraZeneca to develop antisense therapies for cardiovascular, metabolic, renal diseases

AstraZeneca and Isis Pharmaceuticals, Inc. today announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases.

3 Aug 2015

Innovative course helps make medical students more confident about dealing with health disparities

An innovative three-month elective course has helped make some first-year medical students at Albert Einstein College of Medicine more confident about dealing with health disparities they'll likely encounter as physicians, according to a follow-up study published online today in the journal Academic Medicine.

30 Jul 2015

Dietary phosphate appears to cause spikes in blood phosphorus levels

Phosphates artificially added to dairy and cereal products appear to cause bigger spikes in blood phosphorus levels than naturally occurring phosphates, potentially putting harmful stress on kidneys. Too much dietary phosphate stiffens blood vessels, enlarges the heart and is bad for bones, but a new study by Houston Methodist researchers suggests it matters where the phosphates come from.

22 Jul 2015

Early antiretroviral treatment prevents AIDS- and non-AIDS-related diseases in HIV-infected people

Starting antiretroviral therapy early not only prevents serious AIDS-related diseases, but also prevents the onset of cancer, cardiovascular disease, and other non-AIDS-related diseases in HIV-infected people, according to a new analysis of data from the Strategic Timing of AntiRetroviral Treatment (START) study, the first large-scale randomized clinical trial to establish that earlier antiretroviral treatment benefits all HIV-infected individuals.

22 Jul 2015

New drug patiromer could improve potassium levels of patients with diabetic kidney disease

Among patients with diabetic kidney disease and hyperkalemia (elevated potassium levels in the blood), a potentially life-threatening condition, those who received the new drug patiromer, twice daily for four weeks, had significant decreases in potassium levels which lasted through one year, according to a study in the July 14 issue of JAMA.

15 Jul 2015

$Wayne State researchers explore effects of Tocotrienol-rich fraction from palm oil in ESRD patients$

Wayne State researchers explore effects of Tocotrienol-rich fraction from palm oil in ESRD patients

End-stage renal disease (ERSD) is the last stage of chronic kidney disease where the kidneys function at under 10 to 15 percent of their normal capacity. At this stage, kidneys cannot effectively remove waste or excess fluid from the blood system, and dialysis or a kidney transplant is necessary to live.

14 Jul 2015

DaVita Kidney Care recognizes June as National Men's Health Month

DaVita Kidney Care, a division of DaVita HealthCare Partners Inc. and a leading provider of kidney care services, recognizes the month of June as National Men's Health Month and the importance of bringing awareness to the health care issues that affect men.

26 Jun 2015

University of Michigan, AstraZeneca team up to identify novel targets for chronic kidney disease

AstraZeneca today announced a two-year research collaboration with the University of Michigan to advance the treatment of chronic kidney disease (CKD) through the improved understanding of the disease. The collaboration will tackle the challenging area of identifying novel targets for the treatment of CKD, focusing on the use ofpatient tissue and validation of preclinical models.

18 Jun 2015

TUSM researchers reveal how scratching evokes pleasurable sensation in chronic itch patients

It's long been known that scratching evokes a rewarding and pleasurable sensation in patients with chronic itch. Now, researchers in the Department of Dermatology and Temple Itch Center at Temple University School of Medicine may be closer to understanding why.

16 Jun 2015

Tioga Pharmaceuticals announces commencement of asimadoline Phase 2 study for treatment of pruritus

Tioga Pharmaceuticals, a clinical stage biotechnology company, today announced the initiation of a Phase 2 clinical study of asimadoline, a novel, well-studied kappa-opioid receptor specific agonist, for the treatment of pruritus or itching. The double-blind, placebo-controlled clinical study is designed to evaluate the safety, tolerability, and clinical efficacy of asimadoline in patients with pruritus due to atopic dermatitis and is being conducted at 20 clinical study centers in the United States.

11 Jun 2015

Regulus Therapeutics begins RG-012 Phase I clinical study for treatment of Alport syndrome

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that dosing has begun in a first-in-human Phase I clinical study of RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21").

4 Jun 2015

UH researchers identify new method to provide diagnostic information on kidney disease

University of Houston researchers have identified a new, less-invasive method to provide diagnostic information on kidney disease and its severity.

30 May 2015

First European approval of drug to treat genetic kidney disease ADPKD

Otsuka Pharmaceutical Co., Ltd. announced that the European Commission has granted marketing authorisation for JINARC® (tolvaptan) for the treatment of ADPKD in adults who have chronic kidney disease (CKD) stage one to three at initiation of treatment with evidence of rapidly progressing disease

29 May 2015

DaVita Clinical Research announces expansion of clinical trials capabilities in Europe

DaVita Clinical Research (DCR), a specialty contract research organization with services spanning a broad spectrum of drug and device development, today announced an expansion of its clinical trials capabilities in Europe.

28 May 2015

Raising lupus awareness: an interview with Professor Ramsey-Goldman, MD

Lupus is a chronic, autoimmune disease, with many different symptoms so it is hard to diagnose. It affects each person differently and it has an unpredictable disease course with flare ups and quiet time. Some patients describe lupus as if they are riding a roller coaster with blinders on because they cannot always tell when they will feel well or sick...

11 May 2015

Phosphate Therapeutics reports positive results from PT20 trial in people with hyperphosphataemia

Phosphate Therapeutics Limited, a development-stage specialty pharmaceuticals company, today announces positive results from the PEACH pivotal study of PT20 in subjects with hyperphosphataemia related to dialysis dependent chronic kidney disease (DD-CKD).

7 May 2015